A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Phase of Trial: Phase I/II
Latest Information Update: 25 Nov 2018
At a glance
- Drugs Irinotecan (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Gastrointestinal cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 01 Feb 2018 Planned End Date changed from 7 Nov 2020 to 29 Feb 2020.